Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

Kaushal, Monika; Razak, Abdul; Patel, Waseemoddin; Pullattayil, Abdul K.; Kaushal, Ayush

doi:10.1038/s41372-020-00884-9

Cited by 30 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we should consider the use of lower doses of anti-VEGF agents, particularly in infants with smaller BW, because previous reports suggested that lower-than-standard doses were also effective for ROP [19,20]. Some of the previous reports focusing on systemic adverse effects of IVB suggested that it could cause neurodevelopmental disabilities in early childhood [15,21,22], while others showed no relationship between IVB and neurodevelopmental disorders [13,23,24]. Therefore, further analysis is needed to determine whether IVB causes neurodevelopmental disorders.…”

Section: Plos Onementioning

confidence: 99%

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain

et al. 2021

View full text Add to dashboard Cite

Purpose To evaluate the short-term effect on body weight (BW) gain after intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP). Methods This was a retrospective 1:1 matched case-control study. Infants with ROP treated by IVB or photocoagulation (PC) at Shiga University of Medical Science Hospital between April 2010 and December 2019 were included in the study. To match BWs at treatment between the IVB and PC groups, 1:1 matching for BWs at treatment within 100 g was performed. The BW gains for the 7 days before treatment (pre-treatment week), the 7 days after treatment (first post-treatment week), and the period from 7 to 14 days after treatment (second post-treatment week) were compared between the IVB and PC groups. Results Following 1:1 matching, 13 infants in both groups were enrolled in the analysis. The weekly BW gain for the first post-treatment week was significantly lower in the IVB group compared with the PC group (86 g vs. 145 g; P = 0.046), whereas the weekly BW gains for the pre-treatment week (173 g vs. 159 g; P = 0.71) and the second post-treatment week (154 g vs. 152 g; P = 0.73) were comparable between the two groups. The short-term inhibitive effect of IVB on BW gain was particularly observed in infants weighing less than 1500 g at treatment (<1500 g: 47 g vs. ≥1500 g: 132 g; P = 0.03). Conclusion IVB could have a short-term inhibitive effect on BW gain in infants with ROP, and this effect is more likely to occur in infants with a lower BW at the time of treatment.

show abstract

Section: Plos Onementioning

confidence: 99%

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain

et al. 2021

View full text Add to dashboard Cite

show abstract

“…At present, the treatment targeting VEGF/VEGFR has become an important means of tumor treatment. The mechanism is mainly through competitive binding with endogenous VEGF, and inhibiting or reducing the binding of VEGF to vascular endothelial cell surface receptors, thereby inhibiting endothelial cell proliferation and angiogenesis, and finally playing a role in inhibiting tumor growth ( 26 , 27 ).…”

Section: Discussionmentioning

confidence: 99%

Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress

Chen

Hou²,

Zhao³

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

ObjectiveTo investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of colorectal cancer (CRC) and to analyze the effects on brain peptides, intestinal flora, and oxidative stress in CRC patients.MethodsEighty two patients with CRC who were admitted to our hospital from March 2018 to June 2021 were selected as the research subjects and divided into the control group (n = 41) and the observation group (n = 41). The control group was treated with XELOX chemotherapy, and the observation group was additionally treated with bevacizumab, which was repeated every 3 weeks for a total of two treatments. The therapeutic effects of the two groups were evaluated after treatment. The brain-gut peptide index, intestinal flora index and oxidative stress index were detected, and the adverse reactions of the two groups were recorded.ResultsIn the control group, ER was 36.59% (15/41) and DCR was 73.17% (30/41). In the observation group, ER was 63.41% (26/41) and DCR was 90.24% (37/41). ER and DCR in the observation group were higher than those in the control group (P < 0.05). After treatment, the levels of motilin and gastrin in the observation group were lower than those in the control group, and ghrelin was higher than that in the control group (P < 0.05). After treatment, the levels of Bifidobacterium, Lactobacilli and Enterococcus in the observation group were higher than those in the control group, and the level of Escherichia coli was lower than that in the control group (P < 0.05). After treatment, the SOD level of the observation group was lower than that of the control group, and the MDA level was higher than that of the control group.ConclusionBevacizumab combined with chemotherapy has good efficacy in the treatment of colorectal cancer patients, which can effectively improve the gastrointestinal motility of patients, regulate the intestinal flora of the body, rebuild the microecological balance, effectively reduce the oxidative stress response of patients, and reduce the incidence of adverse reactions.

show abstract

“…The disease is currently treated by cryotherapy or laser photocoagulation, both of which can cause retinal damage with loss of the peripheral vision to preserve the central vision. There are presently no approved drug therapies for ROP in the U.S. VEGF inhibitors are often used off-label to treat the disease but have potential safety concerns because of adverse effects on the developing retina and brain in neonates [ 2 , 3 , 7 , 8 , 9 , 10 , 11 , 16 , 17 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

“…There has been intense debate regarding the safety of anti-VEGF therapy for ROP patients. Clinical studies have reported retinal abnormalities, the persistence of peripheral avascular retina, ROP recurrence, retinal detachment, decreased systemic serum VEGF, and underdevelopment of other organ systems in ROP infants who received anti-VEGF therapy [ 2 , 3 , 7 , 8 , 9 , 10 , 11 , 16 , 17 , 18 ]. Unfortunately, a lack of consensus on the safety issue has hindered the approval of anti-VEGF for ROP in the U.S., despite the recent approval of ranibizumab in the European Union.…”

Section: Discussionmentioning

confidence: 99%

Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy

Tian

Dai

et al. 2021

IJMS

View full text Add to dashboard Cite

The retinopathy of prematurity (ROP), a neovascular retinal disorder presenting in premature infants, is the leading causes of blindness in children. Currently, there is no approved drug therapy for ROP in the U.S., highlighting the urgent unmet clinical need for a novel therapeutic to treat the disease. Secretogranin III (Scg3) was recently identified as a disease-selective angiogenic factor, and Scg3-neutralizing monoclonal antibodies were reported to alleviate pathological retinal neovascularization in mouse models. In this study, we characterized the efficacy and safety of a full-length humanized anti-Scg3 antibody (hAb) to ameliorate retinal pathology in oxygen-induced retinopathy (OIR) mice, a surrogate model of ROP, by implementing histological and functional analyses. Our results demonstrate that the anti-Scg3 hAb outperforms the vascular endothelial growth factor inhibitor aflibercept in terms of efficacy and safety to treat OIR mice. Our findings support the development of anti-Scg3 hAb for clinical application.

show abstract

Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

Cited by 30 publications

References 42 publications

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain

Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress

Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy

Contact Info

Product

Resources

About